Since 2012 Samsung Biologics and Biogen have collaborated through Samsung Bioepis Co., Ltd., our joint venture to bring forth biosimilars of advanced biologics. The two companies are committed to bringing biosimilars of advanced biologics to those who need them most.  At the end of 2013, Biogen announced that it had entered into an agreement with Samsung Bioepis to commercialise anti-TNF biosimilar product candidates in Europe, including biosimilars for widely-used therapies to treat conditions such as rheumatoid arthritis, psoriasis and Crohn’s disease. In 2016, the European Commission approved the first two biosimilars from the joint venture for use in the European Union.

Biogen and Samsung Bioepis are also manufacturing partners for the anti-TNF biosimilars, bringing together Biogen's rich heritage and expertise in manufacturing biologics and Samsung Bioepis' technical leadership in manufacturing process development.

These biosimilars are currently manufactured in the same state-of-the-art facilities where Biogen manufactures its originator advanced biologic medicines.